OGT Licenses Patents to Biotype Diagnostics for Microarray Technology Development | GenomeWeb

OGT Licenses Patents to Biotype Diagnostics for Microarray Technology Development

Nov 22, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Oxford Gene Technology today announced it has licensed its patents for detecting DNA sequence variations to Biotype Diagnostics, which will use it to develop a microarray platform.

The rights are valid for the lifetime of the patents and give Biotype certain rights with respect to SNP genotyping, OGT said in a statement. Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Related Articles

Mar 04, 2014

OGT Complements Chromosomal Microarray Portfolio with Acquisition of FISH Probe Firm Cytocell

Premium

Oct 28, 2014

OGT to Commence Clinical Trial for New Array-based Non-invasive Prenatal Test for Down's Syndrome

Premium

Oct 14, 2014

OGT Sees New Medical Research Exome Array as 'Perfect Complement' to Next-gen Sequencing Workflows

Premium

Dec 02, 2014

OGT's FY2014 Revenues Rise 27 Percent on CytoSure Array, Cytocell FISH Sales, NGS Services

Premium

Aug 01, 2014

OGT Receives $300K SBRI Grant to Work on New Variant Interpretation Software Product

Premium

Jul 15, 2014

OGT Expands Pre-implantation Genetic Screening Offering with New Embryo Screen Array

Premium